J. Y. GAUTHIER

The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

Petpiboon Prasit, Z Wang, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 429 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles

Chi‐Chung Chan, S. Boyce, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 399 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Pharmacology of montelukast sodium (Singulair™), a potent and selective leukotriene D₄receptor antagonist

Thomas R. Jones, Marc Labelle, Michel Belley et al. · Canadian Journal of Physiology and Pharmacology · 1995 · 251 citations

Medicine, Pharmacology, Cellular Pharmacology +10

Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits

Brenda L Pennypacker, Le T. Duong, Tara E. Cusick et al. · Journal of Bone and Mineral Research · 2010 · 109 citations

Medicine, Endocrinology, Orthopaedic Surgery +17

From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors

W. Cameron Black, Christopher I. Bayly, Michel Belley et al. · Bioorganic & Medicinal Chemistry Letters · 1996 · 108 citations

Medicine, Medicinal Chemistry, Pharmacology +10